News and Insights

Explore the latest from Delos and our life sciences investment portfolio.

VC Delos Capital Teams Up With Taiwanese Drugmaker to Launch Biotech Startups

Collaboration | May 12, 2026 | Delos News

TRexBio Announces Pipeline Progress, Naming TRB-071 as a CD30 Agonist for Immune-Mediated Diseases and Advancement of Lilly-Partnered TRB-051

Clinical | July 01, 2026 | Portfolio News

Sirius Therapeutics Announces First Patient Dosed in Phase 1/2a Trial of SRSD384, a Novel INHBE-Targeting siRNA for Obesity

Clinical | July 01, 2026 | Portfolio News

Delos Webinar: Capital Efficiency in Biotechnology - Accessing the Global Advantage

Collaboration | June 26, 2026 | Delos News

Rejoni, Inc. Secures $25 Million in Financing to Accelerate the Juveena® Hydrogel System Toward FDA Approval and Launch

Financing | June 16, 2026 | Portfolio News

Eccongene's Elecoglipron, an oral small molecule GLP-1 RA, moves to an extensive Phase III Trial

Clinical | June 08, 2026 | Portfolio News

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine

Clinical | June 02, 2026 | Portfolio News

Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting

Clinical | June 02, 2026 | Portfolio News

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

Acquisition or IPO, Financing | June 01, 2026 | Portfolio News

Phanes Therapeutics announces updated Phase 2 clinical trial results of spevatamig (PT886) in combination with chemotherapy in frontline treatment of metastatic PDAC at the 2026 ASCO annual meeting

Clinical | May 28, 2026 | Portfolio News

Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD

Clinical | May 28, 2026 | Portfolio News

Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) In Ongoing Phase 1/2 ORION-1 Study

Clinical | May 28, 2026 | Portfolio News

Rgenta Therapeutics Presents Positive Preliminary Data from Ongoing Phase 1a/b Clinical Trial of RGT-61159 in Patients with Adenoid Cystic Carcinoma and Colorectal Cancer at the 2026 ASCO Meeting

Clinical | May 21, 2026 | Portfolio News

Imperative Care Appoints Jay Martin as Chief Commercial Officer

Personnel / Awards | May 14, 2026 | Portfolio News

Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor

Clinical | May 13, 2026 | Portfolio News

VC Delos Capital Teams Up With Taiwanese Drugmaker to Launch Biotech Startups

Collaboration | May 12, 2026 | Delos News

Delos Capital and AP Biosciences Inc. Launch Collaboration to Create New Biotech Companies Focused on Next-Generation Antibodies

Collaboration | May 12, 2026 | Delos News

Ensoma to Present Clinical Safety Data from First Participant Dosed with In Vivo HSC Engineering Therapy at ASGCT Annual Meeting

Clinical | May 08, 2026 | Portfolio News

TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis

Clinical | May 07, 2026 | Portfolio News

TRexBio Doses First Patient with Moderate-to-Severe Atopic Dermatitis in Phase 1b Clinical Trial of TRB-061, a TNFR2 Agonist

Clinical | April 29, 2026 | Portfolio News

Avenzo Therapeutics Advances the Combination of CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) in Ongoing Phase 1/2 ORION-1 Study in HR+/HER2- Breast Cancer

Clinical | April 28, 2026 | Portfolio News

Rgenta Therapeutics Announces Two Oral Presentations Highlighting Proprietary RSwitch Technology at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting

Science | April 27, 2026 | Portfolio News

Rgenta Therapeutics Announces RGT-61159 Clinical Poster Presentation at the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Science | April 21, 2026 | Portfolio News

Imperative Care Initiates ADAPT 2.0 Study Evaluating Advanced Clinical Technique Designed to Simplify Acute Ischemic Stroke Treatment

Clinical | April 14, 2026 | Portfolio News

SRSD216 Demonstrates Sustained Lp(a) Reduction and Favorable Safety Profile in Phase 1 Trial

Clinical | March 31, 2026 | Portfolio News

Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

Financing | March 27, 2026 | Portfolio News

Averna Therapeutics Announces Strategic Leadership Expansion

Personnel / Awards | March 26, 2026 | Portfolio News

Imperative Care Initiates CLEAR-IT Clinical Study to Address Critical Gaps in Clinical Standards for Peripheral Thromboembolism

Clinical | March 25, 2026 | Portfolio News

Eccogene Announces First Patient Enrolled in MIST Phase 2a Trial Evaluating ECC4703 as an Adjunct to Semaglutide for the Treatment of Obesity

Clinical | March 17, 2026 | Portfolio News

Imperative Care Announces $100 Million Financing

Financing | March 17, 2026 | Portfolio News

Rgenta Therapeutics Presents Preclinical Data, Unveiling its New Drug Candidate, RGT-0474060, as a Promising Oral PMS1 Inhibitor for the Treatment of Huntington’s Disease

Clinical | February 25, 2026 | Portfolio News

Eccogene Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China

Clinical | February 10, 2026 | Portfolio News

TRexBio Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg Therapeutics

Financing | January 28, 2026 | Portfolio News

Instylla Initiates Commercial Launch with First Use of the Embrace™ Hydrogel Embolic System

Clinical | January 28, 2026 | Portfolio News

Imperative Care Launches Zoom 4S Catheter to Further Advance Company’s Zoom Stroke System for Ischemic Stroke Treatment

Clinical | January 27, 2026 | Portfolio News

Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026

Clinical | January 09, 2026 | Portfolio News

STRM.BIO Raises $8 Million in Series Seed 2 Financing to Advance Non-Viral Gene Delivery Platform for In Vivo Cell Engineering and Gene Therapy

Financing | January 07, 2026 | Portfolio News

Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

Clinical | January 05, 2026 | Portfolio News

Sirius Therapeutics Announces First Patient Dosed in Phase 2 Trial of SRSD216 for siRNA Therapy for Hyperlipoproteinemia(a)

Clinical | December 31, 2025 | Portfolio News

Eccogene Announces First Patient Enrolled in MOSAIC Phase 2a Trial Evaluating ECC4703 and ECC0509, Individually and in Combination, for the Treatment of MASH

Clinical | December 16, 2025 | Portfolio News

Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium

Clinical | December 11, 2025 | Portfolio News

Alpha-9 Oncology's Phase 1 study advances A9-3408, an Actinium-225-based radiotherapeutic, building on the progress of the company’s imaging agent, A9-3202, which entered the clinic last year

Clinical | December 04, 2025 | Portfolio News

Ensoma Announces First Patient Dosed in Phase 1/2 Clinical Trial of EN-374 for Treatment of X-CGD

Clinical | December 01, 2025 | Portfolio News

Alpha-9 Oncology Appoints Paul Blanchfield as Chief Executive Officer

Personnel / Awards | November 10, 2025 | Portfolio News

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

Collaboration | October 08, 2025 | Portfolio News

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate | Avenzo Therapeutics

Clinical | September 29, 2025 | Portfolio News

Avenzo Therapeutics Announces $60 Million Series B Financing

Financing | September 22, 2025 | Portfolio News

Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline

Financing | September 22, 2025 | Portfolio News

Averna Therapeutics named one of Endpoints News 2025 Winners of the Endpoints 11 Awards, Highlighting Biotech’s Most Promising Startups

Personnel / Awards | September 19, 2025 | Portfolio News

Rgenta Therapeutics Receives Orphan Drug Designation from the U.S. FDA for RGT-61159 for the Treatment of Adenoid Cystic Carcinoma (ACC)

Clinical | September 17, 2025 | Portfolio News

Phanes Therapeutics announces first biliary tract carcinoma (BTC) patient dosed in clinical study of spevatamig in combination with chemotherapy

Clinical | September 08, 2025 | Portfolio News

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

Financing | September 03, 2025 | Portfolio News

Imperative Care Announces FDA Clearance of Symphony Thrombectomy System, the First Large-Bore Continuous Vacuum System for Treatment of Pulmonary Embolism

Clinical | September 02, 2025 | Portfolio News

Chuck Alpuche Appointed to President and COO of Imperative Care

Personnel / Awards | August 14, 2025 | Portfolio News

Instylla Gains U.S. FDA Premarket Approval for Embrace™ Hydrogel Embolic System

Clinical | August 07, 2025 | Portfolio News

Cardurion Pharmaceuticals Completes Enrollment in Phase 2 CYCLE Trials Evaluating CRD‑750, a Novel PDE9 inhibitor, in Heart Failure

Clinical | August 06, 2025 | Portfolio News

Instylla Appoints MedTech Leader Sean Boyle as Chief Executive Officer

Personnel / Awards | August 05, 2025 | Portfolio News

Imperative Care Secures FDA Clearance and Initial Cases of the Zoom 7X Catheter, the Newest Innovation in Ischemic Stroke Treatment

Clinical | July 23, 2025 | Portfolio News

Sirius Therapeutics Receives European Medicines Agency (EMA) Authorization to Initiate a Phase 2 Clinical Trial of SRSD107 for Thromboembolic Disorders

Clinical | July 23, 2025 | Portfolio News

Imperative Care Presents Positive Imperative Trial Data from Patients Treated with Aspiration Thrombectomy for M2 Occlusions Using the Zoom System

Clinical | July 15, 2025 | Portfolio News

Verge Medical Acquires RoVo™ System to Advance Peripheral Embolic Protection

Acquisition or IPO | June 30, 2025 | Portfolio News

AltruBio Presents New Preclinical Data at FOCIS 2025 Demonstrating ALTB-268’s Efficacy in T Cell-Mediated Inflammatory Models

Clinical | June 23, 2025 | Portfolio News

Eccogene Announces First Patient Dosed in Phase 1b Trial of AZD5004/ECC5004, a Novel Oral GLP-1 Receptor Agonist, in China

Clinical | June 18, 2025 | Portfolio News

Eccogene to Report Preclinical Data with ECC4703, Showcasing Impact on Lean Muscle Sparing and Fat Loss in Combination with Semaglutide and Tirzepatide

Clinical | June 17, 2025 | Portfolio News

TRexBio Doses First Participant in Phase 1 Trial of TRB-061, a Novel TNFR2 Agonist for Atopic Dermatitis and Other Inflammatory Diseases

Clinical | June 03, 2025 | Portfolio News

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate

Clinical | June 03, 2025 | Portfolio News

CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies

Collaboration | May 19, 2025 | Portfolio News

Sirius Therapeutics Announces Nearly $50 million Financing to Accelerate Clinical Development of siRNA Therapeutics for Cardiometabolic Diseases

Financing | May 09, 2025 | Portfolio News

Eccogene Appoints Dr. Jai Patel as Chief Medical Officer

Personnel / Awards | May 01, 2025 | Portfolio News

Sirius Therapeutics announces U.S. FDA Clearance of IND to Begin Clinical Trial of Novel siRNA Therapy for Hyperlipoproteinemia(a)

Clinical | April 09, 2025 | Portfolio News

TRexBio Expands Leadership Team with Appointments of Ariella Kelman, M.D., as Chief Medical Officer and Brandon Hants, MBA, as Chief Financial Officer

Personnel / Awards | April 08, 2025 | Portfolio News

Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

Personnel / Awards | March 17, 2025 | Portfolio News

Ensoma Receives Rare Pediatric Disease and Orphan Drug Designations for EN-374 for Treatment of Chronic Granulomatous Disease

Clinical | February 13, 2025 | Portfolio News

Rejoni completes patient enrollment in pivotal clinical study of a Novel Treatment for the Prevention of Intrauterine Adhesions, the Juveena® Hydrogel System.

Clinical | February 04, 2025 | Portfolio News

Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer

Personnel / Awards | January 30, 2025 | Portfolio News

Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate

Collaboration | January 07, 2025 | Portfolio News

Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders

Clinical | December 10, 2024 | Portfolio News

Rgenta Therapeutics Announces Strategic Alliance with GSK to Develop RNA-Targeted Small Molecule Splice Modulators

Collaboration | December 04, 2024 | Portfolio News

Avenzo Therapeutics Provides Corporate Update and Announces Closing of Series A/A-1 Financing

Collaboration, Financing | November 18, 2024 | Portfolio News

TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development

Financing | November 13, 2024 | Portfolio News

Ensoma Unveils Three Programs Leveraging In Vivo Hematopoietic Stem Cell Engineering Platform to Target Genetic, Immune and Oncological Diseases

Clinical | November 06, 2024 | Portfolio News

Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals

Financing | October 23, 2024 | Portfolio News

Eccogene Receives Milestone Payment of $60 Million from AstraZeneca Following Dosing of the First Patient in Global Phase 2b Program of ECC5004/AZD5004 for the Treatment of Obesity and Type 2 Diabetes

Financing | October 23, 2024 | Portfolio News

Rgenta Therapeutics Announces First Patients Dosed in Phase 1a/b Clinical Trial of RGT-61159, an Oral Small Molecule Targeting MYB, in Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC)

Clinical | October 08, 2024 | Portfolio News

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

Financing | September 12, 2024 | Portfolio News

Tanvex BioPharma Forging Strategic Alliance With Bora Pharmaceuticals

Collaboration | September 05, 2024 | Portfolio News

Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors

Financing | July 25, 2024 | Portfolio News

FDA clears surgical hydrogel nerve cap for preventing phantom limb pain in amputees

Clinical | July 22, 2024 | Portfolio News

Cardurion Pharmaceuticals Announces $260 Million Series B Financing to Advance Its Pipeline of Innovative Medicines for Cardiovascular Diseases

Financing | July 16, 2024 | Portfolio News

Rgenta Therapeutics Announces FDA Clearance of IND Application for RGT-61159, an Oral Small Molecule RNA Modulator Designed to Halt Disease-Driver MYB Production in Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC)

Clinical | July 10, 2024 | Portfolio News

Exsilio Therapeutics Launches with $82 Million Series A Financing to Develop Redosable Genomic Medicines for A Broad Range of Diseases

Financing | June 25, 2024 | Portfolio News

AltruBio Secures up to $225M Oversubscribed Series B Financing to Advance the Clinical Development of Novel Immune Checkpoint Enhancer Program

Financing | May 21, 2024 | Portfolio News

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

Financing | May 07, 2024 | Portfolio News

Phanes Therapeutics’ PT217 granted Fast Track Designation by the FDA

Clinical | April 08, 2024 | Portfolio News

Sirius Therapeutics Announces Dosing of First Subject in Chinese Phase 1 Clinical Trial of FXI siRNA Anticoagulant

Clinical | April 01, 2024 | Portfolio News

Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline

Financing | March 26, 2024 | Portfolio News

Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections

Clinical | February 27, 2024 | Portfolio News

Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases

Collaboration | November 09, 2023 | Portfolio News

Phanes Therapeutics, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate PT886 in Combination with KEYTRUDA® (pembrolizumab)

Collaboration | October 16, 2023 | Portfolio News

Sirius Therapeutics Raised Nearly US$100 Million to Accelerate Clinical Development of siRNA Therapeutics

Financing | October 09, 2023 | Portfolio News